Want to see BTCY full AI Analyst Report?
Top Page
Biotricity
(OTC:BTCY)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.10
▼(-13.64% Downside)
Action:Reiterated
Date:07/27/26
The score is primarily constrained by weak financial resilience (negative equity, meaningful debt, and ongoing cash burn) despite improving operations and revenue/margin trends. Technical indicators also point to a bearish trend (below key moving averages with negative MACD), and valuation support is limited due to negative earnings and no dividend yield.
Positive Factors
Multi-year revenue growth
Sustained top-line growth over multiple years indicates successful product adoption and market penetration in remote cardiac monitoring. A growing revenue base supports scale, operating leverage, and potential to fund product development and sales expansion over the coming quarters.
Negative Factors
Deeply negative shareholders' equity
Material negative equity signals accumulated losses and a weakened capital base, limiting financial flexibility. This condition heightens refinancing risk, reduces ability to absorb shocks, and can constrain strategic investments or contract negotiations over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
Sustained top-line growth over multiple years indicates successful product adoption and market penetration in remote cardiac monitoring. A growing revenue base supports scale, operating leverage, and potential to fund product development and sales expansion over the coming quarters.
Read all positive factors
Biotricity (BTCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.23M
Dividend YieldN/A
Average Volume (3M)43.96K
Price to Earnings (P/E)―
Beta (1Y)-0.02
Revenue Growth16.01%
EPS Growth83.47%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.11
Shares Outstanding20,074,675
10 Day Avg. Volume84,984
30 Day Avg. Volume43,962
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.20
Price to Sales (P/S)0.40
P/FCF Ratio-8.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biotricity Business Overview & Revenue Model
Company Description
Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States. The company's efforts are dedicated to supplying remote monitoring c...
How the Company Makes Money
Biotricity generates revenue primarily by providing cardiac monitoring solutions to healthcare providers and/or diagnostic service workflows tied to those devices. Its revenue model generally combines (1) sales or placement of proprietary cardiac ...
Biotricity Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call conveyed clear operational momentum: double-digit revenue growth, meaningful gross margin expansion (+516 bps), consecutive positive EBITDA quarters (3) and six consecutive quarters of positive free cash flow, plus strong digital user and provider network expansion. Remaining challenges include a continued net loss ($1.1M), modest absolute revenue scale ($4.0M quarterly), concentration of revenue in technology fees (91.2%), and dependence on future FDA/regulatory clearances and large-account sales cycles. Overall, the positives (margin improvement, recurring revenue, cash-flow and EBITDA momentum, product traction and distribution reach) outweigh the remaining execution and scale risks.Positive Updates
Revenue Growth
Total revenue for the quarter was $4.0M, up 10.2% year-over-year from $3.6M in the prior-year quarter.
Negative Updates
Net Loss Remains
Net loss attributable to common stockholders was $1.1M for the quarter (loss per share $0.042), improved from $1.3M (loss per share $0.054) year-over-year but still reflecting overall quarterly net losses.
Read all updates
Q3-2026 Updates
Positive
Negative
Revenue Growth
Total revenue for the quarter was $4.0M, up 10.2% year-over-year from $3.6M in the prior-year quarter.
Read all positive updates
Company Guidance
In the Q3 FY2026 call (period ended Dec. 31, 2025) management guided to continued top-line growth and a shift to profitability in calendar 2026—expecting to turn net‑income positive this year—citing Q3 revenue of $4.0M (up 10.2% vs. $3.6M), technology fees at 91.2% of revenue, gross profit $3.3M (+17.6% YoY) and gross margin 81.5% (up 516 bps from 76.4%), operating expenses $2.8M (down 4.2% YoY) with SG&A down 8.2% (~$195K) and R&D up $72K, EBITDA of $280K ($0.01/share) marking three consecutive quarters of positive EBITDA and six consecutive quarters of positive free cash flow, a net loss of $1.1M (vs. $1.3M) and loss per share $0.042 (vs. $0.054); they also highlighted user growth from 4,500 to >44,000 in two years, >2,500 providers supporting ~400,000 patients annually, expanded Biocore Pro pilots, GPO access to >90% of U.S. hospitals, and stated additional margin and expense improvements are expected with upcoming FDA clearances and international approvals.Biotricity Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Jun 2025 | Mar 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.00M | 13.79M | 12.06M | 9.64M | 7.65M |
| Gross Profit | 12.95M | 10.56M | 8.36M | 5.44M | 4.57M |
| EBITDA | 1.69M | -3.21M | -8.90M | -16.07M | -18.56M |
| Net Income | -2.40M | -8.42M | -14.09M | -18.66M | -29.13M |
Balance Sheet | |||||
| Total Assets | 6.45M | 5.64M | 5.94M | 6.51M | 16.68M |
| Cash, Cash Equivalents and Short-Term Investments | 149.79K | 365.14K | 786.06K | 570.46K | 12.07M |
| Total Debt | 27.06M | 26.09M | 23.88M | 19.55M | 15.35M |
| Total Liabilities | 39.41M | 35.66M | 35.92M | 26.36M | 18.82M |
| Stockholders Equity | -32.96M | -30.01M | -29.98M | -19.85M | -2.14M |
Cash Flow | |||||
| Free Cash Flow | -718.96K | -2.38M | -6.69M | -13.55M | -15.19M |
| Operating Cash Flow | -718.96K | -2.38M | -6.69M | -13.55M | -15.16M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -29.77K |
| Financing Cash Flow | 557.74K | 1.93M | 6.74M | 2.00M | 25.17M |
Biotricity Technical Analysis
Negative
0.11
Price Trends
0.12
Negative
0.17
Negative
0.27
Negative
Market Momentum
>-0.01
Negative
47.29
Neutral
29.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTCY, the sentiment is Negative. The current price of 0.11 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.12, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.29 is Neutral, neither overbought nor oversold. The STOCH value of 29.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTCY.
Biotricity Risk Analysis
Biotricity disclosed 50 risk factors in its most recent earnings report. Biotricity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We are vulnerable to changes in political and economic conditions, including the effects of tariffs and/or international trade wars and disruptions to remittances. Q1, 2025
2.
New or increased tariffs or other trade restrictions could have a material adverse effect on our business, financial condition, results of operations and cash flows. Q1, 2025
Biotricity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $8.40M | -0.27 | -382.50% | ― | -100.00% | 87.37% | |
45 Neutral | $5.70M | -0.18 | -2239.18% | ― | 33.77% | -20.22% | |
43 Neutral | $2.23M | -0.98 | 12.85% | ― | 16.01% | 83.47% | |
42 Neutral | $8.50M | -0.56 | -358.44% | ― | -0.71% | 58.20% |
* Healthcare Sector Average
BTCY
Biotricity
0.11
-0.33
-75.00%
VVOS
Vivos Therapeutics
0.32
-4.08
-92.68%
ADGM
Adagio Medical Holdings
0.73
-0.62
-45.78%
HSCS
Heart Test Laboratories, Inc.
2.00
-1.59
-44.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.